Georgina Espigol-Frigole
Overview
Explore the profile of Georgina Espigol-Frigole including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Corbera-Bellalta M, Kamberovic F, Alba-Rovira R, Planas-Rigol E, Prieto-Gonzalez S, Farran-Centelles N, et al.
Ann Rheum Dis
. 2025 Mar;
PMID: 40074597
Objectives: Blocking interleukin (IL)-6-receptor with tocilizumab has been a major advance in the treatment of giant-cell arteritis (GCA), supporting a crucial role of IL-6 receptor signalling. However, nearly half of...
2.
Espigol-Frigole G, Prieto-Gonzalez S, Marco-Hernandez J, Corbera-Bellalta M, Cid M
Rheumatology (Oxford)
. 2025 Mar;
64(Supplement_1):i74-i78.
PMID: 40071431
Objectives: Both temporal artery biopsy (TAB) and imaging are widely used to support the diagnosis of giant cell arteritis (GCA). The objective of this study was to compare the use...
3.
Espigol-Frigole G, Cid M
Rheumatology (Oxford)
. 2025 Mar;
64(Supplement_1):i1.
PMID: 40071403
No abstract available.
4.
Draibe J, Espigol-Frigole G, Cid M, Prados M, Guillen E, Villacorta J, et al.
Rheumatology (Oxford)
. 2024 Oct;
PMID: 39352795
Objectives: ANCA-associated vasculitis (AAV) are chronic diseases with relapses that associate organic damage because of the disease and its treatment. Avacopan is a new treatment indicated for AAV. We present...
5.
Estupinan-Moreno E, Hernandez-Rodriguez J, Li T, Ciudad L, Andres-Leon E, Terron-Camero L, et al.
J Autoimmun
. 2024 May;
146:103240.
PMID: 38754238
Background: Giant cell arteritis (GCA) is an immune-mediated large-vessels vasculitis with complex etiology. Although the pathogenic mechanisms remain poorly understood, a central role for CD4 T cells has been demonstrated....
6.
Bosch P, Espigol-Frigole G, Cid M, Mollan S, Schmidt W
Lancet Rheumatol
. 2024 Apr;
6(6):e384-e396.
PMID: 38574747
Since its first clinical description in 1890, extensive research has advanced our understanding of giant cell arteritis, leading to improvements in both diagnosis and management for affected patients. Imaging studies...
7.
Fernandes-Serodio J, Prieto-Gonzalez S, Espigol-Frigole G, Rios-Garces R, Gomez-Caverzaschi V, Araujo O, et al.
J Intern Med
. 2024 Mar;
295(5):651-667.
PMID: 38462959
Background: Microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) are the two major antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Objectives: To characterize a homogenous AAV cohort and to assess the...
8.
Beca S, Alba M, Hernandez-Rodriguez J, Espigol-Frigole G, Prieto-Gonzalez S, Cid M, et al.
Semin Arthritis Rheum
. 2024 Feb;
66:152412.
PMID: 38387195
Objectives: To analyze pregnancy outcomes of patients with primary systemic vasculitis followed in a third-level referral center. Methods: Retrospective cohort study of all pregnant women with systemic vasculitis followed between...
9.
Cid M, Espigol-Frigole G
Lancet Rheumatol
. 2024 Jan;
3(9):e606-e607.
PMID: 38287609
No abstract available.
10.
Bettiol A, Urban M, Padoan R, Groh M, Lopalco G, Egan A, et al.
Lancet Rheumatol
. 2024 Jan;
5(12):e707-e715.
PMID: 38251561
Background: Interleukin-5 (IL-5) inhibitors represent novel therapies for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the effectiveness and safety of the IL-5 receptor inhibitor benralizumab in a European cohort...